Natera has appointed Michael Little as senior vice president of research and development. Prior to Natera, Little was the global head of diagnostics development at Novartis. Before that, he served as vice president of research and development, vice president of medical affairs, vice president of regulatory and scientific affairs, and the vice president of program management at Novartis Diagnostics.
Cold Spring Harbor Laboratory has appointed George Yancopoulos to its board of trustees. He currently serves as chief scientific officer of Regeneron Pharmaceuticals and president of Regeneron Laboratories. He joined Regeneron in 1989 as its scientific founder. Together with key members of his team, he is a principal inventor and developer of Regeneron’s four FDA-approved drugs.
Veracyte said this week that it has appointed Tina Nova to its board of directors. She currently serves as president and CEO of molecular diagnostics firm Molecular Stethoscope, and she previously has served as senior VP and general manager of Illumina's oncology business unit. Nova also was a co-founder, director, president, and CEO of Genoptix Medical Laboratory, which was acquired by Novartis Pharmaceuticals in 2011. She serves on the board of directors of Arena Pharmaceuticals and is vice chairman of the board of directors for the Rady Pediatric Genomics and Systems Medicine Institute.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.